Childhood-onset severe hypereosinophilic asthma: efficacy of benralizumab

Childhood-onset severe hypereosinophilic asthma: efficacy of benralizumab

Bibliographic Details
Main Authors:	Jocelyne Just, Melisande Bourgoin, Flore Amat, Nathalie Cottel, Nathalie Lambert, Stephanie Wanin
Format:	Article
Language:	English
Published:	European Respiratory Society 2020-12-01
Series:	ERJ Open Research
Online Access:	http://openres.ersjournals.com/content/6/4/00339-2020.full

Similar Items

Idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab
by: Koki Fujii, et al.
Published: (2020-11-01)

Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma
by: FitzGerald JM, et al.
Published: (2019-12-01)

Efficacy and safety of benralizumab in Japanese patients with severe, uncontrolled eosinophilic asthma
by: Ken Ohta, et al.
Published: (2018-04-01)

The clinical profile of benralizumab in the management of severe eosinophilic asthma
by: Francesco Menzella, et al.
Published: (2016-12-01)

Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study
by: Takanori Numata, et al.
Published: (2020-08-01)

Benralizumab: a unique IL-5 inhibitor for severe asthma
by: Tan LD, et al.
Published: (2016-04-01)

Real-life cost-effectiveness of benralizumab in patients with severe asthma
by: A. Padilla-Galo, et al.
Published: (2021-05-01)

Benralizumab in the treatment of severe asthma: design, development and potential place in therapy
by: Pelaia C, et al.
Published: (2018-03-01)

Molecular Targets for Biological Therapies of Severe Asthma: Focus on Benralizumab and Tezepelumab
by: Shih-Lung Cheng
Published: (2021-07-01)

Clinical-economic impact of mepolizumab in patients with severe hypereosinophilic asthma
by: Diego Bagnasco, et al.
Published: (2020-08-01)

Identification of distinct phenotypes related to benralizumab responsiveness in patients with severe eosinophilic asthma.
by: Hideyasu Yamada, et al.
Published: (2021-01-01)

Effectiveness of Benralizumab in Severe Eosinophilic Asthma Under Conditions of Routine Clinical Practice
by: Alemany-Francés, M.L, et al.
Published: (2022)

Assessment of an accessorized pre-filled syringe for home-administered benralizumab in severe asthma
by: Ferguson GT, et al.
Published: (2018-04-01)

Reductions in Eosinophil Biomarkers by Benralizumab in Patients With Asthma
by: Mirhojjat Khorasanizadeh, et al.
Published: (2017-07-01)

Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series
by: Menzella F, et al.
Published: (2021-02-01)

Serum microRNAs as Tool to Predict Early Response to Benralizumab in Severe Eosinophilic Asthma
by: José A. Cañas, et al.
Published: (2021-01-01)

Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis
by: Carlos Martínez-Rivera, et al.
Published: (2021-01-01)

Rapid Effect of Benralizumab for Hypereosinophilia in a Case of Severe Asthma with Eosinophilic Chronic Rhinosinusitis
by: Hiroaki Tsurumaki, et al.
Published: (2019-07-01)

New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic
by: Caminati M, et al.
Published: (2019-05-01)

Clinical and economic comparison of utilization of reslizumab, mepolizumab and benralizumab in the treatment of severe eosinophilic asthma
by: S. K. Zyryanov, et al.
Published: (2020-12-01)

Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma
by: Corrado Pelaia, et al.
Published: (2018-01-01)

Comparative Efficacy and Safety of Dupilumab and Benralizumab in Patients with Inadequately Controlled Asthma: A Systematic Review
by: Koichi Ando, et al.
Published: (2020-01-01)

Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial
by: Andrew Menzies-Gow, et al.
Published: (2019-09-01)

Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma
by: Corrado Pelaia, et al.
Published: (2020-09-01)

Daily patient-reported health status assessment improvements with benralizumab for patients with severe, uncontrolled eosinophilic asthma
by: O'Quinn S, et al.
Published: (2019-01-01)

Cycling therapy with benralizumab and dupilumab for severe eosinophilic asthma with eosinophilic chronic rhinosinusitis and eosinophilic otitis media
by: Satoshi Hamada, et al.
Published: (2021-07-01)

Efficacy and use of benralizumab in patients with eosinophilic chronic rhinosinusitis
by: G.L. Fadda, et al.
Published: (2021-03-01)

Single-Use Autoinjector Functionality And Reliability For At-Home Administration Of Benralizumab For Patients With Severe Asthma: GRECO Trial Results
by: Ferguson GT, et al.
Published: (2019-10-01)

Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
by: Kayser MZ, et al.
Published: (2021-07-01)

Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases
by: Menzella F, et al.
Published: (2015-10-01)

Targeted therapy in bronchial asthma. Benralizumab: focus on patients using systemic glucocorticosteroids
by: N. P. Kniajeskaia, et al.
Published: (2020-11-01)

Determinants of allergic rhinitis in young children with asthma.
by: Lise Moussu, et al.
Published: (2014-01-01)

Spontaneous resolution of atopic dermatitis incidental to participation in benralizumab clinical trial for severe, uncontrolled asthma: a case report
by: David N. Pham
Published: (2021-03-01)

Successful management of eosinophilic chronic rhinosinusitis complicated by severe asthma using dupilumab, following negative initial results with benralizumab
by: Isao Suzaki, et al.
Published: (2021-01-01)

Onset of Effect, Changes in Airflow Obstruction and Lung Volume, and Health-Related Quality of Life Improvements with Benralizumab for Patients with Severe Eosinophilic Asthma: Phase IIIb Randomized, Controlled Trial (SOLANA)
by: Panettieri RA Jr, et al.
Published: (2020-02-01)

Hypereosinophilic syndromes
by: Giuseppe Civardi, et al.
Published: (2013-04-01)

Hypereosinophilic syndromes
by: Goldman Michel, et al.
Published: (2007-09-01)

Hypereosinophilic syndrome complicated by severe vascular damage and gangrene
by: Thilo Gambichler, MD, et al.
Published: (2019-09-01)

Rapid onset of effect of benralizumab on respiratory symptoms in a patient with eosinophilic granulomatosis with polyangiitis
by: Angelo Coppola, et al.
Published: (2020-01-01)

Mepolizumab asthma treatment failure due to refractory airway eosinophilia, which responded to benralizumab
by: Alistair Cook, et al.
Published: (2021-05-01)